BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kinoshita T. Congenital Defects in the Expression of the Glycosylphosphatidylinositol-Anchored Complement Regulatory Proteins CD59 and Decay-Accelerating Factor. Seminars in Hematology 2018;55:136-40. [DOI: 10.1053/j.seminhematol.2018.04.004] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 3.5] [Reference Citation Analysis]
Number Citing Articles
1 Li C, Dong X, Wang H, Shao Z. The Role of T Lymphocytes in the Pathogenesis of Paroxysmal Nocturnal Hemoglobinuria. Front Immunol 2021;12:777649. [PMID: 35003092 DOI: 10.3389/fimmu.2021.777649] [Reference Citation Analysis]
2 Bushey RT, Gottlin EB, Campa MJ, Patz EF Jr. Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis. PLoS One 2021;16:e0252577. [PMID: 34133431 DOI: 10.1371/journal.pone.0252577] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
3 Garred P, Tenner AJ, Mollnes TE. Therapeutic Targeting of the Complement System: From Rare Diseases to Pandemics. Pharmacol Rev 2021;73:792-827. [PMID: 33687995 DOI: 10.1124/pharmrev.120.000072] [Cited by in Crossref: 42] [Cited by in F6Publishing: 45] [Article Influence: 42.0] [Reference Citation Analysis]
4 Murakami Y. Diseases Associated With GPI Anchors. Comprehensive Glycoscience 2021. [DOI: 10.1016/b978-0-12-819475-1.00025-0] [Reference Citation Analysis]
5 Sosicka P, Ng BG, Freeze HH. Congenital Disorders of Glycosylation. Comprehensive Glycoscience 2021. [DOI: 10.1016/b978-0-12-819475-1.00013-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Elieh Ali Komi D, Shafaghat F, Kovanen PT, Meri S. Mast cells and complement system: Ancient interactions between components of innate immunity. Allergy 2020;75:2818-28. [PMID: 32446274 DOI: 10.1111/all.14413] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 9.5] [Reference Citation Analysis]
7 Kudlay DA, Bakirov BA, Pavlov VN. Biotechnological products for the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria: currently available and in development. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2020;19:164-172. [DOI: 10.24287/1726-1708-2020-19-3-164-172] [Reference Citation Analysis]
8 Ptushkin VV, Kulagin AD, Lukina EA, Davydkin IL, Konstantinova TS, Shamrai VS, Minaeva NV, Kudlay DA, Gapchenko EV, Markova OA, Borozinets AY. [Results of phase Ib open multicenter clinical trial of the safety, pharmacokinetics and pharmacodynamics of first biosimilar of eculizumab in untreated patients with paroxysmal nocturnal hemoglobinuria during induction of therapy]. Ter Arkh 2020;92:77-84. [PMID: 33346448 DOI: 10.26442/00403660.2020.07.000818] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
9 Bakirov BA, Kudlay DA, Pavlov VN. Eculizumab in the treatment of complement system disorders including paroxysmal nocturnal hemoglobinuria. Voprosy gematologii/onkologii i immunopatologii v pediatrii 2020;19:193-199. [DOI: 10.24287/1726-1708-2020-19-2-193-199] [Reference Citation Analysis]
10 Schröder-Braunstein J, Kirschfink M. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management. Mol Immunol 2019;114:299-311. [PMID: 31421540 DOI: 10.1016/j.molimm.2019.08.002] [Cited by in Crossref: 36] [Cited by in F6Publishing: 40] [Article Influence: 12.0] [Reference Citation Analysis]
11 Leth JM, Leth-Espensen KZ, Kristensen KK, Kumari A, Lund Winther AM, Young SG, Ploug M. Evolution and Medical Significance of LU Domain-Containing Proteins. Int J Mol Sci 2019;20:E2760. [PMID: 31195646 DOI: 10.3390/ijms20112760] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
12 Risitano AM. Therapeutic complement modulation for hematological diseases: Where we stand and where we are going. Semin Hematol 2018;55:113-7. [PMID: 30032746 DOI: 10.1053/j.seminhematol.2018.05.012] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]